{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-24-000114","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.578037+00:00","generated_at":"2026-05-31T14:22:39.016438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolus Q2 revenue $66.9M (+36% YoY); raises FY2024 guidance to $260-270M; first positive non-GAAP operating income","bullets":["Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.","GAAP operating loss improved to $7.7M; first positive non-GAAP operating income of $1.1M.","Raised full-year 2024 net revenue guidance to $260M-$270M (top end 34% YoY growth).","PMA submitted to FDA for Evolysse Lift and Smooth fillers; approval and launch expected H2 2025.","Added 770 new customer accounts; total ~14,000 since launch; reorder rate ~70%."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-24-000114","json":"https://secwatch.observer/filing/0001570562-24-000114.json","markdown":"https://secwatch.observer/filing/0001570562-24-000114.md","text":"https://secwatch.observer/filing/0001570562-24-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/0001570562-24-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/eols-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:22:39.016438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}